Patients must have histologically confirmed ER+ and/or PR+, HER-, early invasive breast cancer. Participants must have histologically confirmed invasive breast cancer; all histologic subtypes are eligible Histologically confirmed HER-negative localized breast cancer by core biopsy. Primary operable, non-metastatic invasive carcinoma of the breast, confirmed histologically by core biopsy. Participants must have histologically or cytologically confirmed invasive breast cancer Patients must have histologically confirmed new diagnosis of breast cancer Histologically confirmed invasive cancer of the breast have a histologically confirmed diagnosis of ER+ breast cancer; Histologically confirmed diagnosis of invasive breast cancer Diagnosis of histologically confirmed invasive primary rectal carcinoma Histologically proven invasive adenocarcinoma of breast Histologically-confirmed, primary, invasive breast cancer diagnosed within years of study entry Patients with histologically confirmed intact primary cancer that is confirmed invasive carcinoma of the breast, with at least . cm residual disease as measured by mammography, ultrasound, or breast magnetic resonance imaging (MRI) after neoadjuvant anthracycline based chemotherapy Subjects have histologically confirmed adenocarcinoma of the breast - all breast cancer subtypes are allowed Histologically confirmed breast cancer Newly diagnosed histologically or cytologically confirmed operable invasive breast cancer defined as cT or T, N-, and M Histologically confirmed diagnosis of invasive breast cancer Histologically confirmed diagnosis of invasive breast cancer Newly diagnosed histologically confirmed invasive breast cancer Histologically confirmed HER-positive metastatic breast cancer Histologically confirmed diagnosis of invasive or non-invasive breast cancer Histologically confirmed diagnosis of invasive cervical cancer Histologically confirmed invasive primary breast cancer Participants must have histologically confirmed invasive breast cancer; all histologic subtypes are eligible Histologically confirmed invasive breast cancer Female with histologically confirmed breast cancer Histologically confirmed unilateral primary invasive adenocarcinoma of the breast Histologically confirmed unilateral or bilateral primary invasive carcinoma of the breast. Histologically confirmed invasive breast cancer with a primary tumor size of greater than (>) cm Non-metastatic operable primary invasive HER-positive carcinoma of the breast that is histologically confirmed, and adequately excised Histologically or cytologically confirmed invasive breast carcinoma with local recurrence or radiological evidence of metastatic disease. Patients must have histologically confirmed invasive breast cancer with a primary tumor >= cm in greatest dimension as measured by clinical or radiologic examination Postmenopausal women with histologically or cytologically confirmed invasive, ER+/HER- (defined by local guidelines) metastatic or inoperable, locally advance breast cancer History of histologically-confirmed bilateral breast cancer Patients must have a histologically confirmed diagnosis of hormone receptor positive, HER negative invasive breast carcinoma Histologically or cytologically confirmed invasive breast cancer with distant metastasis PHASE II: Participants must have histologically confirmed invasive breast cancer; all histologic subtypes are eligible Non-metastatic histologically confirmed primary invasive breast carcinoma that was operable Participants must have histologically confirmed HER+ (+ by immunohistochemistry and/or FISH ratio >= .) invasive breast cancer; central confirmation of HER status is not required Histologically confirmed invasive cancer of the breast. Participants must have histologically confirmed invasive breast cancer; all histologic subtypes are eligible Histologically confirmed invasive breast carcinoma Histologically confirmed Stage I to III invasive breast cancer. Subjects may have more than one synchronous primary breast tumor. Patients must have histologically or cytologically confirmed invasive cancer of the breast Histologically confirmed primary invasive adenocarcinoma of the breast Histologically or cytologically confirmed invasive breast carcinoma at local institution Have histologically confirmed breast or ovarian carcinoma Histologically or cytologically confirmed invasive carcinoma of the breast Histologically or cytologically confirmed invasive breast carcinoma Histologically or cytologically confirmed HER-positive invasive breast cancer, with Stage IV disease; Histologically confirmed unilateral primary invasive adenocarcinoma of the breast Women histologically diagnosed with carcinoma of the breast Patients must have evidence of histologically confirmed invasive breast cancer, stage I, II or III, and be at least years post diagnosis Histologically confirmed carcinoma of the breast Non-metastatic histologically confirmed primary invasive breast carcinoma Patients must be women with histologically confirmed primary invasive carcinoma of the breast (stage I, II, or III) with no evidence of metastatic disease (M) or with histologically confirmed ductal carcinoma in situ (DCIS); if patient has undergone breast cancer surgery, she must have recovered from all side-effects of surgery Patients with histologically confirmed invasive breast cancer, stage I - IV, treated at Lyndon B. Johnson General Hospital in the Harris Health System Prior history of histologically confirmed bilateral invasive breast cancer A history of histologically-confirmed bilateral invasive breast cancer Histologically confirmed metastatic breast cancer Have a histologically-confirmed diagnosis of breast cancer Histologically confirmed cT-, N breast cancer Participants must have histologically or cytologically confirmed invasive or in-situ carcinoma of the breast Group I: Diagnosis of histologically confirmed invasive breast cancer Group II: Diagnosis of histologically confirmed invasive breast cancer Women with histologically proven invasive breast cancer and no distant metastases and; Patients must have histologically confirmed invasive breast cancer